NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Role of Microglia in the Pathogenesis of Progressive Multiple Sclerosis

Active Not RecruitingN/A

Sponsor: Turku University Hospital

Conditions: Multiple Sclerosis

Countries: Finland

Our aim is to evaluate whether translocator binding protein (TSPO)-imaging correlates to Expanded Disability Status Scale (EDSS) and other disease progression-related clinical and paraclinical parameters in a homogenous cohort of 40-50-year old MS-patients, who are at risk of progression. The A2A-AR expression in this cohort will also be studied using the adenosine A2A-receptor (A2A-AR)-binding radioligand 11C-TMSX. The study cohort will also form the basis for a later follow-up study, which will be performed to evaluate the prognostic value of baseline TSPO-imaging in terms of disease progression. TSPO-imaging could thus be used as an imaging biomarker to help identifying patients to therapeutically prevent progression of MS. At the 5 year time point synaptic density will be evaluated using 11C-UCB-J radioligand and PET imaging.

Eligibility overview

Sex: ALL

Age: 40 Years to 50 Years

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* RRMS, age 40-50 years, MS-diagnosis for a minimum of five years.

Exclusion Criteria:

* Previous or present treatment with immunosuppressive medication or biologicals. - Steroid treatment within 30 days of evaluation

Locations (1)

Turku, Southwest Finland, Finland